You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Accession NumberDB00288  (APRD00788)
TypeSmall Molecule

Amcinonide is a corticosteroid. [Wikipedia]

External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cyclocortointment0.1 %topicalGlaxosmithkline Inc1997-01-20Not applicableCanada
Cyclocortcream0.1 %topicalGlaxosmithkline Inc1996-09-12Not applicableCanada
Cyclocortlotion0.1 %topicalGlaxosmithkline Inc1996-09-12Not applicableCanada
Cyclocort Crm 0.1%cream.1 %topicalLederle Cyanamid Canada Inc.1978-12-311997-01-29Canada
Cyclocort Lot 0.1%lotion.1 %topicalLederle Cyanamid Canada Inc.1983-12-311997-01-29Canada
Cyclocort Ont 0.1%ointment.1 %topicalLederle Cyanamid Canada Inc.1983-12-311997-01-29Canada
Ratio-amcinonidecream0.1 %topicalTeva Canada Limited2003-09-18Not applicableCanada
Ratio-amcinonidelotion0.1 %topicalTeva Canada Limited2004-05-06Not applicableCanada
Ratio-amcinonideointment0.1 %topicalTeva Canada Limited2004-05-05Not applicableCanada
Taro-amcinonideointment0.1 %topicalTaro Pharmaceuticals IncNot applicableNot applicableCanada
Taro-amcinonidecream0.1 %topicalTaro Pharmaceuticals Inc2003-02-13Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Amcinonidecream1 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2003-05-15Not applicableUs
Amcinonideointment1 mg/gtopicalTaro Pharmaceuticals U.S.A., Inc.2003-03-19Not applicableUs
Amcinonidecream1 mg/gtopicalTaro Pharmaceuticals U.S.A., Inc.2002-05-31Not applicableUs
Amcinonidelotion1 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2002-11-06Not applicableUs
Amcinonideointment1 mg/gtopicalE. Fougera & Co. a division of Fougera Pharmaceuticals Inc.2014-04-03Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
MycodermNot Available
PenticortNot Available
VisdermNot Available
Brand mixturesNot Available
SaltsNot Available
CAS number51022-69-6
WeightAverage: 502.5717
Monoisotopic: 502.236681679
Chemical FormulaC28H35FO7
2-[(1'S,2'S,4'R,8'S,9'S,11'S,12'R,13'S)-12'-fluoro-11'-hydroxy-9',13'-dimethyl-16'-oxo-5',7'-dioxaspiro[cyclopentane-1,6'-pentacyclo[²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-14',17'-dien-8'-yl]-2-oxoethyl acetate
DescriptionThis compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassPregnane steroids
Direct ParentGluco/mineralocorticoids, progestogins and derivatives
Alternative Parents
  • Progestogin-skeleton
  • 20-oxosteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • Hydroxysteroid
  • Halo-steroid
  • 9-halo-steroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Alpha-acyloxy ketone
  • Acetate salt
  • Cyclic alcohol
  • Meta-dioxolane
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Halohydrin
  • Fluorohydrin
  • Carboxylic acid ester
  • Oxacycle
  • Organoheterocyclic compound
  • Carboxylic acid derivative
  • Acetal
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organofluoride
  • Organohalogen compound
  • Carbonyl group
  • Alkyl halide
  • Alkyl fluoride
  • Alcohol
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
IndicationFor the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
PharmacodynamicsAmcinonide is a topical corticosteroid. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Amcinonide reduces or inhibits the actions of chemicals in the body that cause inflammation, redness, and swelling. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. When in an ointment form, amcinonide also helps the skin maintain moisture.
Mechanism of actionThe mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Amcinonide has affinity for the glucocorticoid receptor. It has weak affinity for the progesterone receptor, and virtually no affinity for the mineralocorticoid, estrogen, or androgen receptors.
Related Articles
AbsorptionTopical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.
Volume of distributionNot Available
Protein bindingNot Available

Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys.

Route of eliminationCorticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
Half lifeNot Available
ClearanceNot Available
ToxicityResults from acute toxicity studies do not indicate that any risk of acute intoxication is to be expected following a single dermal application of an overdose (application over a large area under conditions favorable to absorption) or inadvertent oral ingestion.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Predicted ADMET features
Human Intestinal Absorption+0.9643
Blood Brain Barrier+0.9897
Caco-2 permeable-0.5844
P-glycoprotein substrateSubstrate0.7713
P-glycoprotein inhibitor IInhibitor0.7198
P-glycoprotein inhibitor IIInhibitor0.5596
Renal organic cation transporterNon-inhibitor0.7608
CYP450 2C9 substrateNon-substrate0.8615
CYP450 2D6 substrateNon-substrate0.9016
CYP450 3A4 substrateSubstrate0.7307
CYP450 1A2 substrateNon-inhibitor0.8688
CYP450 2C9 inhibitorNon-inhibitor0.8732
CYP450 2D6 inhibitorNon-inhibitor0.8982
CYP450 2C19 inhibitorNon-inhibitor0.9188
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8999
Ames testNon AMES toxic0.8886
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.4315 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9488
hERG inhibition (predictor II)Non-inhibitor0.5298
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
  • Altana inc
  • Taro pharmaceutical industries ltd
  • Astellas pharma us inc
Dosage forms
Creamtopical1 mg/g
Lotiontopical1 mg/g
Ointmenttopical1 mg/g
Creamtopical0.1 %
Lotiontopical0.1 %
Ointmenttopical0.1 %
Creamtopical.1 %
Lotiontopical.1 %
Ointmenttopical.1 %
Unit descriptionCostUnit
Amcinonide 0.1% Cream 60 gm Tube84.29USD tube
Amcinonide 0.1% Ointment 60 gm Tube84.29USD tube
Amcinonide 0.1% Cream 30 gm Tube28.71USD tube
Amcinonide 0.1% Cream 15 gm Tube20.99USD tube
Amcinonide 0.1% cream1.68USD g
Cyclocort 0.1 % Cream0.62USD g
Cyclocort 0.1 % Ointment0.62USD g
Cyclocort 0.1 % Lotion0.52USD g
Ratio-Amcinonide 0.1 % Ointment0.33USD g
Ratio-Amcinonide 0.1 % Cream0.29USD g
Taro-Amcinonide 0.1 % Cream0.29USD g
Ratio-Amcinonide 0.1 % Lotion0.27USD g
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Experimental Properties
logP2.3Not Available
Predicted Properties
Water Solubility0.00774 mg/mLALOGPS
pKa (Strongest Acidic)13.63ChemAxon
pKa (Strongest Basic)-3.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area99.13 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity127.88 m3·mol-1ChemAxon
Polarizability52.23 Å3ChemAxon
Number of Rings6ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Mass Spec (NIST)Not Available
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Synthesis Reference

Schultz, W., Sieger, G.M. and Krieger, C.: British Patent 1,442,925; July 14,1976; assigned to
American Cyanamid Company.

General ReferencesNot Available
External Links
ATC CodesD07AC11
AHFS Codes
  • 84:06.00
PDB EntriesNot Available
FDA labelDownload (143 KB)
MSDSDownload (48.1 KB)
Drug Interactions
AldesleukinAmcinonide may decrease the antineoplastic activities of Aldesleukin.
CeritinibAmcinonide may increase the hyperglycemic activities of Ceritinib.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin can be decreased when used in combination with Amcinonide.
DeferasiroxThe risk or severity of adverse effects can be increased when Amcinonide is combined with Deferasirox.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Amcinonide.
Food InteractionsNot Available


Pharmacological action
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
Uniprot ID:
Molecular Weight:
85658.57 Da
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Grossman R, Yehuda R, Golier J, McEwen B, Harvey P, Maria NS: Cognitive effects of intravenous hydrocortisone in subjects with PTSD and healthy control subjects. Ann N Y Acad Sci. 2006 Jul;1071:410-21. [PubMed:16891588 ]
  4. Rautanen A, Eriksson JG, Kere J, Andersson S, Osmond C, Tienari P, Sairanen H, Barker DJ, Phillips DI, Forsen T, Kajantie E: Associations of body size at birth with late-life cortisol concentrations and glucose tolerance are modified by haplotypes of the glucocorticoid receptor gene. J Clin Endocrinol Metab. 2006 Nov;91(11):4544-51. Epub 2006 Aug 8. [PubMed:16895953 ]
  5. Hammer F, Stewart PM: Cortisol metabolism in hypertension. Best Pract Res Clin Endocrinol Metab. 2006 Sep;20(3):337-53. [PubMed:16980198 ]
  6. Shaw JR, Gabor K, Hand E, Lankowski A, Durant L, Thibodeau R, Stanton CR, Barnaby R, Coutermarsh B, Karlson KH, Sato JD, Hamilton JW, Stanton BA: Role of glucocorticoid receptor in acclimation of killifish (Fundulus heteroclitus) to seawater and effects of arsenic. Am J Physiol Regul Integr Comp Physiol. 2007 Feb;292(2):R1052-60. Epub 2006 Oct 12. [PubMed:17038445 ]
  7. Sher L: Combined dexamethasone suppression-corticotropin-releasing hormone stimulation test in studies of depression, alcoholism, and suicidal behavior. ScientificWorldJournal. 2006 Oct 31;6:1398-404. [PubMed:17086345 ]
Pharmacological action
General Function:
Structural molecule activity
Specific Function:
Plays important roles in the innate immune response as effector of glucocorticoid-mediated responses and regulator of the inflammatory process. Has anti-inflammatory activity (PubMed:8425544). Plays a role in glucocorticoid-mediated down-regulation of the early phase of the inflammatory response (By similarity). Promotes resolution of inflammation and wound healing (PubMed:25664854). Functions ...
Gene Name:
Uniprot ID:
Molecular Weight:
38713.855 Da
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Serres M, Comera C, Schmitt D: Annexin 1 regulation in human epidermal cells. Cell Mol Biol (Noisy-le-grand). 1994 Jul;40(5):701-6. [PubMed:7981624 ]
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23